Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

SSRI Antidepressants Not Tied to Cardiovascular Conditions

By Drug Discovery Trends Editor | March 23, 2016

Commonly prescribed antidepressants, called selective serotonin reuptake inhibitors (SSRIs) are not associated with an increased risk of heart conditions, such as heart attacks and stroke, according to recent research published in the BMJ.

While depression is known to increase the risk of cardiovascular problems, it has not been clear whether that risk is tied to antidepressant use. Previously, it’s been thought that SSRIs may affect coagulation, leading to cardiovascular disease — but this association has not been confirmed.

The Food and Drug Administration and the European Medicines Association both issued warnings in 2011 about the risk of taking high doses of citalopram (Celexa), one of the most commonly prescribed antidepressants. A dose of citalopram should not exceed 40 mg per day, both agencies said.

Yet, according to the BMJ study, citalopram, the most commonly prescribed antidepressant among patients in the study, was not associated with an increased risk of arrhythmia, even at higher doses. Still, the authors note that higher doses may pose a risk, because only 18 percent of the citalopram prescriptions in the study were for higher doses.

Researchers at The University of Nottingham analyzed a cohort of nearly 239,000 patients, ages 20 to 64, who had been diagnosed with depression. The patients were monitored for heart attacks, stroke, or transient ischaemic attacks and arrhythmia. When the researchers looked at tricyclic antidepressants, SSRIs and other types of antidepressants — and adjusted for age, gender, alcohol and tobacco use, other conditions and use of other medications — they didn’t see an increase in cardiovascular conditions among patients on SSRIs.

In a 5-year period, 772 patients had a myocardial infraction; 1,106 had a stroke of transient ischemic attack; and 1,452 had arrhythmia. But there was no evidence that SSRIs increased the risk of these cardiovascular conditions.

But during the first four weeks of taking tricyclic and related antidepressants, there was double the risk of experiencing arrhythmia.

“In addition, we found some indication that SSRIs were associated with a reduced risk of heart attacks, particularly with the use of fluoxetine (Prozac),” said study author Carol Coupland, of Nottingham University.

It’s important to note that these results do not prove a causative link, because this is an observational study.

Antidepressant use in the U.S. has skyrocketed: Adults in the U.S. consumed four times more antidepressants in the late 2000s than they did in the early 1990s. Antidepressants are the third most frequently taken drug in the U.S. and researchers estimate that 8 to 10 percent of the population is taking an antidepressant, according to the Centers for Disease Control and Prevention.


Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50